Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
Recruiting · NCT07033598 · Registry updated 2026-08-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, leukemia, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm | Recruiting | Phase 2 | 2026-08-18 | NCT07033598 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| H. Lee Moffitt Cancer Center and Research Institute | 162 |
| MDS/MPN International Working Group (UK Sponsor) | 1 |
| Sobi, Inc. | 12 |
| Theradex | 4 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| King's College Hospital, NHS Foundation Trust | London | United Kingdom | 1 |
| Mayo Clinic Rochester | Rochester | United States | 133 |
| MD Anderson Cancer Center | Houston | United States | 589 |
| Moffitt Cancer Center | Tampa | United States | 523 |
| The Christie, NHS Foundation Trust | Manchester | United Kingdom | 1 |
| Winship Cancer Institute at Emory | Atlanta | United States | 1 |